Clinical TrialsPositive early interim data from the Ph1/2 CARDINAL trial showed that low doses of '701 drove clinically meaningful responses in patients with high baseline BCR-ABL transcript levels.
Financial PositionTERN has a substantial cash reserve of $358M, providing operational expenses coverage into 2028.
Market PotentialBased on analysis, TERN-701 provides significant market opportunity, and TERN-601 offers additional potential upside.